ADAMTS13 and thrombotic thrombocytopenic purpura: Duration of caplacizumab therapy with academic center follow-up was 1 month after hospital discharge for all TTP Pathway patients based on ADAMTS13 recovery, except for the patient who declined follow-up: that patient was treated locally for 3 months and outpatient ADAMTS13 data were not available.